Related Experiment Video

Updated: Sep 6, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

NCOA4: An Immunomodulation-Related Prognostic Biomarker in Colon Adenocarcinoma and Pan-Cancer

Chenzheng Gu1, Wenjing Chang1, Junlu Wu1

  • 1Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.

Journal of Oncology
|June 27, 2022
PubMed

Insights

Low expression of nuclear receptor coactivator 4 (NCOA4) is linked to poorer survival in several cancers, including renal carcinoma. NCOA4 may serve as a predictive biomarker for colon adenocarcinoma (COAD).

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Cancer development involves complex pathways requiring thorough understanding.
  • Nuclear receptor coactivator 4 (NCOA4) has emerged as a potential predictive biomarker in renal cancer.
  • Investigating NCOA4's role can offer insights into cancer progression and therapeutic strategies.

Purpose of the Study:

  • To analyze NCOA4 expression patterns and prognostic relevance across various malignancies.
  • To explore the association between NCOA4 and clinicopathological features, including immune cell infiltration.
  • To investigate NCOA4 DNA methylation and its functional pathways in oncogenesis.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases.
  • Employed multiple bioinformatics approaches to analyze NCOA4 expression and methylation.
  • Correlated NCOA4 expression with overall survival and clinicopathological features.

Main Results:

  • Low NCOA4 expression correlated with poor overall survival in cholangiocarcinoma, colon adenocarcinoma, and clear cell renal carcinoma.
  • Analyzed NCOA4 DNA methylation in normal and tumor tissues.
  • Identified potential functional pathways involved in NCOA4-mediated oncogenesis.

Conclusions:

  • Downregulation of NCOA4 is associated with a poor prognosis in multiple cancer types.
  • NCOA4 demonstrates potential as a predictive biomarker, particularly for colon adenocarcinoma (COAD).
  • Further research into NCOA4 pathways may reveal novel therapeutic targets.

More Related Videos

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

501
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
442